Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.48 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | HINT1 | P49773 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | KRAS | P01116 | 3/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21609617 | 1.00 | POLB (0.54) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL20924348 | 1.00 | POLB (0.54) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL20924422 | 1.00 | POLB (0.54) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL14750407 | 1.00 | POLB (0.54) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL20924553 | 1.00 | POLB (0.54) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL14750417 | 1.00 | POLB (0.54) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL19954095 | 0.95 | POLB (0.54) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL20710405 | 0.94 | POLB (0.62) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL20832624 | 0.94 | POLB (0.62) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL16156404 | 0.90 | POLB (0.52) | POLBFUT5P2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11058705-B2 | Drug formulations | ASTEX PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200352976-A1 | HYPOMETHYLATING AGENTS FOR USE IN TREATMENT OF CANCER | ASTEX PHARMACEUTICALS, INC. | 2020-11-12 | — | — | US | disclosed |
| WO-2020227297-A1 | HYPOMETHYLATING AGENTS FOR USE IN TREATMENT OF CANCER | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2020-11-12 | — | — | WO | disclosed |
| US-20200155588-A1 | DRUG FORMULATIONS | ASTEX PHARMACEUTICALS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-10517886-B2 | Drug formulations | ASTEX PHARMACEUTICALS, INC. (US) | 2019-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155588-A1 | DRUG FORMULATIONS | MCL1, DNMT3A, TET2 | POLB 677/4885FUT5 3024/4885P2RY2 4299/4885 |
| US-11058705-B2 | Drug formulations | MCL1, DNMT3A, TET2 | POLB 677/4885FUT5 3024/4885P2RY2 4299/4885 |
| US-20200352976-A1 | HYPOMETHYLATING AGENTS FOR USE IN TREATMENT OF CANCER | DNMT1, MGMT, UNG | POLB 82/4885FUT5 864/4885P2RY2 3883/4885 |
| US-10517886-B2 | Drug formulations | MCL1, DNMT3A, TET2 | POLB 677/4885FUT5 3024/4885P2RY2 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.